Respicardia

OverviewSuggest Edit

Respicardia is dedicated to improving the lives of heart failure patients by developing implantable therapies designed to improve respiratory rhythm management and cardiovascular health. The first product, the remedē® System, is an implantable stimulation device that is designed to restore a more normal breathing pattern during sleep for patients with central sleep apnea. Respicardia® is committed to improving cardiovascular health…one breath at a time.
TypePrivate
Founded2006
HQHopkins, US
Websiterespicardia.com

Latest Updates

Employees (est.) (Oct 2020)73(+2%)
Cybersecurity ratingCMore

Key People/Management at Respicardia

B. Kristine Johnson

B. Kristine Johnson

Director
Peter Sommerness

Peter Sommerness

President and CEO, Director
Tim Hauch

Tim Hauch

Chief Financial Officer
Kirk Nielsen

Kirk Nielsen

Director
Robin Germany

Robin Germany

Chief Medical Officer
Jonathan A. Rennert

Jonathan A. Rennert

Director
Show more

Respicardia Office Locations

Respicardia has an office in Hopkins
Hopkins, US (HQ)
12400 Whitewater Dr #150
Show all (1)

Respicardia Financials and Metrics

Summary Metrics

Founding Date

2006

Respicardia total Funding

$149.1 m

Respicardia latest funding size

$58.50 m

Time since last funding

3 years ago

Respicardia investors

Respicardia's latest funding round in December 2017 was reported to be $58.5 m. In total, Respicardia has raised $149.1 m
Show all financial metrics

Respicardia Cybersecurity Score

Cybersecurity ratingPremium dataset

C

79/100

SecurityScorecard logo

Respicardia Online and Social Media Presence

Embed Graph

Respicardia News and Updates

CMS Grants New Technology Add-on Payment to the remedē® System for the Treatment of Central Sleep Apnea

MINNETONKA, Minn., Aug. 6, 2018 /PRNewswire/ -- Respicardia, Inc., a medical technology company developing innovative therapies that improve cardiovascular health, today announced that the Centers for Medicare and Medicaid Services (CMS) has approved a New Technology Add-On Payment (NTAP) ...

Respicardia Blogs

Treatment Benefits of the remedē® System Sustained Through 36 Months in Patients with Central Sleep Apnea

Respicardia, Inc., the manufacturer of the only FDA-approved active implantable device for the treatment of central sleep apnea (CSA), today announced the publication of the 24- and 36-month data from the remedē® System Pivotal Trial in the peer-reviewed journal SLEEP....

Therapy Update: Implanted Neurostimulators for Sleep Apnea

By Sree Roy, Sleep Review Magazine Inspire Medical, Respicardia, LivaNova, and Nyxoah share the latest data on their devices.

The Valley Hospital Introduces Sleep Apnea Advance

The Valley Hospital is one of only two sites in New Jersey and the tri-state area currently using a new implantable device to treat adult patients with central sleep apnea. Central sleep apnea is a serious condition in which a person’s sleep is interrupted...

Device delivers sleep apnea relief for retired NASA engineer

By Greg Sullivan Al Harbury is no stranger to innovation. He worked for Lockheed Martin and later as an aerospace system engineer with NASA’s Ames Research Center in California, before retiring to North Carolina. But a little more than a year ago, the 87-year-old Clemmons, North Carolina man bega…

UCHealth first in region to offer latest technology for central sleep apnea

By: Kelly Tracer, UCHealth LOVELAND, Colo. (April 4, 2019) – UCHealth is the first health system in the Rocky Mountain region to offer the latest, implantable treatment option for people with central sleep apnea. In a recent breakthrough procedure at UCHealth Medical Center of the Rockies in Lovela…

CMS Grants Outpatient Pass-through Payment to the remedē® System for the Treatment of Central Sleep Apnea

Pass-through Payment to Provide Additional Medicare Reimbursement for the remedē System
Show more

Respicardia Frequently Asked Questions

  • When was Respicardia founded?

    Respicardia was founded in 2006.

  • Who are Respicardia key executives?

    Respicardia's key executives are B. Kristine Johnson, Peter Sommerness and Tim Hauch.

  • How many employees does Respicardia have?

    Respicardia has 73 employees.

  • Who are Respicardia competitors?

    Competitors of Respicardia include Novian Health, Obalon Therapeutics and VisCardia.

  • Where is Respicardia headquarters?

    Respicardia headquarters is located at 12400 Whitewater Dr #150, Hopkins.

  • Where are Respicardia offices?

    Respicardia has an office in Hopkins.

  • How many offices does Respicardia have?

    Respicardia has 1 office.